Court skeptical of bid to cut abortion pill access
The panel questioned whether Louisiana can revive a challenge that the Supreme Court already paused while the FDA reviews mifepristone safety.
- On Wednesday, Louisiana Attorney General Liz Murrill appeared before a federal appellate court challenging FDA policies that permit abortion drug mifepristone prescriptions via telehealth and mail delivery.
- Murrill's case, part of a five-state legal effort, targets a 2023 FDA revision removing in-person doctor visit requirements; plaintiffs cite the Comstock Act, a 19th-century law prohibiting mailing obscene materials.
- Appellate judges appeared skeptical during Wednesday's hearing, questioning Louisiana Solicitor General Benjamin Aguiaga's request to repeat legal actions the Supreme Court has already stymied.
- Murrill expressed hope that President Donald Trump's FDA administrator nominee, Dr. Heidi Overton, could unilaterally eliminate the telehealth policy, potentially rendering the lawsuit unnecessary.
- While the FDA conducts a safety review due in October, the Trump administration has maintained existing mifepristone access despite pressure from anti-abortion groups.
12 Articles
12 Articles
Appeals against mifepristone have repeatedly encountered obstacles in the Supreme Court on grounds of legitimacy, and the appellate court, which twice ruled that the easing of the statute of limitations violated the statutory procedure, is wary of the possibility of revoking its judgement.
Omaha World-Herald
Court skeptical of bid to cut abortion pill access
A U.S. appeals court on Wednesday appeared skeptical of a bid by the Republican-led state of Louisiana to curtail access to the abortion drug mifepristone by blocking a 2023 rule that allowed the medication to be prescribed via telemedicine and…
Louisiana Illuminator
KTBSLouisiana AG returns to 5th Circuit seeking end to telehealth abortion meds
Louisiana Attorney General Liz Murrill made a return appearance before a federal appellate court Wednesday in her effort to strike down Biden-era health policy that allows abortion drug prescriptions without an in-person doctor’s visit.
Chaos and Confusion Around Women’s Health
Earlier today, the Fifth Circuit Court of Appeals heard oral arguments in State of Louisiana et al. v. Food and Drug Administration et al., a federal lawsuit targeting mifepristone, one of many in a long line of attacks on abortion pills. In this case, the court is being asked to force the FDA to reimpose in-person dispensing requirements, effectively blocking all avenues for obtaining mifepristone — including by mail, via telehealth, and at pha…
Coverage Details
Bias Distribution
- 64% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
